131 related articles for article (PubMed ID: 36642374)
21. Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents.
Deng M; Xu-Monette ZY; Pham LV; Wang X; Tzankov A; Fang X; Zhu F; Visco C; Bhagat G; Dybkaer K; Chiu A; Tam W; Zu Y; Hsi ED; You H; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Parsons BM; Hagemeister F; van Krieken JH; Piris MA; Winter JN; Li Y; Xu B; Liu P; Young KH
Mol Cancer Res; 2021 Feb; 19(2):249-260. PubMed ID: 33154093
[TBL] [Abstract][Full Text] [Related]
22. [B-cell lymphomas with concurrent myc and bcl-2/IgH or bcl-6 translocations].
Luo DL; Liu YH; Zhang F; Xu FP; Yan LX; Chen J; Xu J; Luo XL; Zhuang HG
Zhonghua Bing Li Xue Za Zhi; 2013 Sep; 42(9):584-8. PubMed ID: 24314242
[TBL] [Abstract][Full Text] [Related]
23. Diffuse Large B-Cell Lymphoma Version 1.2016.
Zelenetz AD; Gordon LI; Wierda WG; Abramson JS; Advani RH; Andreadis CB; Bartlett N; Byrd JC; Fayad LE; Fisher RI; Glenn MJ; Habermann TM; Lee Harris N; Hernandez-Ilizaliturri F; Hoppe RT; Horwitz SM; Kaminski MS; Kelsey CR; Kim YH; Krivacic S; LaCasce AS; Lunning M; Nademanee A; Porcu P; Press O; Rabinovitch R; Reddy N; Reid E; Roberts K; Saad AA; Sokol L; Swinnen LJ; Vose JM; Yahalom J; Zafar N; Dwyer M; Sundar H
J Natl Compr Canc Netw; 2016 Feb; 14(2):196-231. PubMed ID: 26850490
[TBL] [Abstract][Full Text] [Related]
24. Prognostic Significance of BCL-2 and BCL-6 Expression in MYC-positive DLBCL.
Li L; Zhang X; Zhang T; Song Z; Hu G; Li W; Li L; Qiu L; Qian Z; Zhou S; Liu X; Feng L; Pan Y; Zhai Q; Meng B; Ren X; Fu K; Wang P; Wang X; Zhang H
Clin Lymphoma Myeloma Leuk; 2018 Oct; 18(10):e381-e389. PubMed ID: 29983382
[TBL] [Abstract][Full Text] [Related]
25. Clinical significance of 'double-hit' and 'double-expression' lymphomas.
Ma Z; Niu J; Cao Y; Pang X; Cui W; Zhang W; Li X
J Clin Pathol; 2020 Mar; 73(3):126-138. PubMed ID: 31615842
[TBL] [Abstract][Full Text] [Related]
26. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
[TBL] [Abstract][Full Text] [Related]
27. Clinical implications of phosphorylated STAT3 expression in De Novo diffuse large B-cell lymphoma.
Ok CY; Chen J; Xu-Monette ZY; Tzankov A; Manyam GC; Li L; Visco C; Montes-Moreno S; Dybkær K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Zhao X; Ponzoni M; Ferreri AJ; Bertoni F; Farnen JP; Møller MB; Piris MA; Winter JN; Medeiros LJ; Young KH
Clin Cancer Res; 2014 Oct; 20(19):5113-23. PubMed ID: 25124685
[TBL] [Abstract][Full Text] [Related]
28. Transcriptional positive cofactor 4 promotes breast cancer proliferation and metastasis through c-Myc mediated Warburg effect.
Luo P; Zhang C; Liao F; Chen L; Liu Z; Long L; Jiang Z; Wang Y; Wang Z; Liu Z; Miao H; Shi C
Cell Commun Signal; 2019 Apr; 17(1):36. PubMed ID: 30992017
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of bromodomain proteins for the treatment of human diffuse large B-cell lymphoma.
Trabucco SE; Gerstein RM; Evens AM; Bradner JE; Shultz LD; Greiner DL; Zhang H
Clin Cancer Res; 2015 Jan; 21(1):113-22. PubMed ID: 25009295
[TBL] [Abstract][Full Text] [Related]
30. Rare cases of primary central nervous system anaplastic variant of diffuse large B-cell lymphoma.
Xu T; Jia Q; Wang Y; Liu Y; Han D; Li P; Ma J; Fan L; Yan Q; Guo S; Li M; Wang Z
Diagn Pathol; 2019 May; 14(1):45. PubMed ID: 31109360
[TBL] [Abstract][Full Text] [Related]
31. The Frequency of Double Expresser in Selected Cases of High Grade Diffuse Large B-Cell Lymphomas.
Naseem M; Asif M; Khadim MT; Ud-Din H; Jamal S; Shoaib I
Asian Pac J Cancer Prev; 2020 Apr; 21(4):1103-1107. PubMed ID: 32334477
[TBL] [Abstract][Full Text] [Related]
32. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy.
Savage KJ; Johnson NA; Ben-Neriah S; Connors JM; Sehn LH; Farinha P; Horsman DE; Gascoyne RD
Blood; 2009 Oct; 114(17):3533-7. PubMed ID: 19704118
[TBL] [Abstract][Full Text] [Related]
33. LncRNA FIRRE is activated by MYC and promotes the development of diffuse large B-cell lymphoma via Wnt/β-catenin signaling pathway.
Shi X; Cui Z; Liu X; Wu S; Wu Y; Fang F; Zhao H
Biochem Biophys Res Commun; 2019 Mar; 510(4):594-600. PubMed ID: 30739786
[TBL] [Abstract][Full Text] [Related]
34. Decreased CD11c-positive dendritic cells in the tumor microenvironment predict double-hit/triple-hit genotype and survival in diffuse large B-cell lymphoma.
Yuan CT; Chuang SS; Cheng PY; Chang K; Wang H; Tsai JH; Liau JY; Chou WC
J Pathol Clin Res; 2022 Sep; 8(5):436-447. PubMed ID: 35715938
[TBL] [Abstract][Full Text] [Related]
35. MYC is a positive regulator of choline metabolism and impedes mitophagy-dependent necroptosis in diffuse large B-cell lymphoma.
Xiong J; Wang L; Fei XC; Jiang XF; Zheng Z; Zhao Y; Wang CF; Li B; Chen SJ; Janin A; Gale RP; Zhao WL
Blood Cancer J; 2017 Jul; 7(7):e0. PubMed ID: 28686226
[TBL] [Abstract][Full Text] [Related]
36. Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma.
Derenzini E; Agostinelli C; Imbrogno E; Iacobucci I; Casadei B; Brighenti E; Righi S; Fuligni F; Ghelli Luserna Di Rorà A; Ferrari A; Martinelli G; Pileri S; Zinzani PL
Oncotarget; 2015 Mar; 6(9):6553-69. PubMed ID: 25544753
[TBL] [Abstract][Full Text] [Related]
37. Histone deacetylase inhibitor romidepsin induces efficient tumor cell lysis via selective down-regulation of LMP1 and c-myc expression in EBV-positive diffuse large B-cell lymphoma.
Shin DY; Kim A; Kang HJ; Park S; Kim DW; Lee SS
Cancer Lett; 2015 Aug; 364(2):89-97. PubMed ID: 25790907
[TBL] [Abstract][Full Text] [Related]
38. Primary central nervous system diffuse large B-cell lymphoma shows an activated B-cell-like phenotype with co-expression of C-MYC, BCL-2, and BCL-6.
Li X; Huang Y; Bi C; Yuan J; He H; Zhang H; Yu Q; Fu K; Li D
Pathol Res Pract; 2017 Jun; 213(6):659-665. PubMed ID: 28552541
[TBL] [Abstract][Full Text] [Related]
39. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
Johnson NA; Slack GW; Savage KJ; Connors JM; Ben-Neriah S; Rogic S; Scott DW; Tan KL; Steidl C; Sehn LH; Chan WC; Iqbal J; Meyer PN; Lenz G; Wright G; Rimsza LM; Valentino C; Brunhoeber P; Grogan TM; Braziel RM; Cook JR; Tubbs RR; Weisenburger DD; Campo E; Rosenwald A; Ott G; Delabie J; Holcroft C; Jaffe ES; Staudt LM; Gascoyne RD
J Clin Oncol; 2012 Oct; 30(28):3452-9. PubMed ID: 22851565
[TBL] [Abstract][Full Text] [Related]
40. P53 expression correlates with poorer survival and augments the negative prognostic effect of MYC rearrangement, expression or concurrent MYC/BCL2 expression in diffuse large B-cell lymphoma.
Wang XJ; L Jeffrey Medeiros ; Bueso-Ramos CE; Tang G; Wang S; Oki Y; Desai P; Khoury JD; Miranda RN; Tang Z; Reddy N; Li S
Mod Pathol; 2017 Feb; 30(2):194-203. PubMed ID: 27739436
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
